nach oben

Neuroradiology

Erschienen in:

01.08.2004 | Diagnostic Neuroradiology

A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours

verfasst von: C. Colosimo, M. V. Knopp, X. Barreau, E. Gérardin, M. A. Kirchin, F. Guézénoc, K. P. Lodemann

Erschienen in: Neuroradiology | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Abstract

A two-centre intra-individual crossover study was performed in 23 patients with suspected high-grade glioma or metastases to assess and compare the safety and enhancement characteristics of two different MRI contrast media (gadobenate dimeglumine, Gd-BOPTA and gadoterate meglumine, Gd-DOTA) at equivalent doses of 0.1 mmol/kg body weight. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and T1-weighted images 0, 2, 4, 6, 8 and 15 min after injection. T1-weighted images with magnetisation transfer contrast were acquired 12 min after injection. Qualitative assessment by blinded, off-site readers (reader 1: 19 patients; reader 2: 21) and on-site investigators (23) revealed significant (P ≤0.005) overall preference for Gd-BOPTA over Gd-DOTA for contrast enhancement (Gd-BOPTA preferred in 18, 15 and 18 cases; Gd-DOTA in 0, 1 and 1 and no preference in 1, 5 and 4; off-site readers 1 and 2, and on-site investigators, respectively). A similar significant preference for Gd-BOPTA was expressed by off-site readers and on-site investigators for lesion-to-brain contrast, lesion delineation, internal lesion structure, and overall image preference. Quantitative assessment by off-site readers revealed significantly (p<0.05) greater lesion enhancement with Gd-BOPTA than with Gd-DOTA at all times from 2 min after injection.

Healy ME, Hesselink JR, Press GA, Middleton MS (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165: 619–624PubMed

Byrne TN (1994) Imaging of gliomas. Semin Oncol 21: 162–171PubMed

Runge VM, Muroff LR, Wells JW (1997) Principles of contrast enhancement in the evaluation of brain diseases: an overview. J Magn Reson Imaging 7: 5–13PubMed

de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl. 1]: S161–S168

Yuh WTC, Fisher DJ, Engelken JD, et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180: 485–491PubMed

Myhr G, Rinck PA, Børseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33: 405–409PubMed

Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35: 490–494PubMed

Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Slavand MG (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35: 173–177PubMed

Brugières P, Gaston A, Degryse HR, et al (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36: 27–30PubMed

10.

Åkeson P, Jonsson E, Haugen I, Holtas S (1995) Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 37: 229–233CrossRefPubMed

11.

Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30: 75–78PubMed

12.

Grossman RI, Rubin DI, Hunter G, et al (2000) Magnetic resonance imaging in patients with central nervous system pathology. A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35: 412–419CrossRefPubMed

13.

Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT (2001) Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45: 457–463CrossRefPubMed

14.

Runge VM, Kirsch JE, Burke VJ, et al (1992) High dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2: 9–18PubMed

15.

Yuh WTC, Engelken JD, Muhonen MG, Fisher DJ, Erhardt JC (1992) Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. AJNR 13: 335–345PubMed

16.

Haustein J, Laniado M, Niendorf H-P, et al (1993) Triple dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186: 855–860PubMed

17.

Yuh WTC, Halloran JI, Mayr NA, Fisher DJ, Nguyen HD, Simonson TM (1994) Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 4: 242–249

18.

Yuh WTC, Fisher DJ, Runge VM, et al (1994) Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. AJNR 15: 1037–1051PubMed

19.

Yuh WTC, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ (1995) The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. AJNR 16: 373–380PubMed

20.

Van Dijk P, Sijens PE, Schmitz PI, Oudkerk M (1997) Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 15: 535–541PubMed

21.

Sze G, Johnson C, Kawamura Y, et al (1998) Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR 19: 821–828PubMed

22.

Yuh WTC, Maley JE (1998) Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin North Am 6: 113–124

23.

Anon. ProHance® (gadoteridol injection) package insert. Bracco Diagnostics, Princeton

24.

Anon. Omniscan® (gadodiamide injection) package insert. Nycomed-Amersham, Princeton

25.

Cavagna FM, Maggioni F, Castelli PM, et al (1997) Gadolinium chelates with weak binding to serum proteins. Invest Radiol 32: 780–796PubMed

26.

Colosimo C, Ruscalleda J, Korves M, et al (2001) Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 36: 72–81PubMed

27.

Runge VM, Armstrong MR, Barr RG, et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36: 65–71PubMed

28.

Runge VM, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37: 269–280CrossRefPubMed

29.

Schneider G, Kirchin MA, Pirovano G, et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 14: 525–539CrossRefPubMed

30.

Balériaux D, Colosimo C, Ruscalleda J, et al (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44: 191–203CrossRefPubMed

31.

Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measurement 20: 37–46

32.

Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577–584PubMed

33.

Parizel PM, Degryse HR, Gheuens J, et al (1989) Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13: 378–385

34.

Knopp MV, Runge VM, Essig M, et al (2004) Primary and secondary brain tumors: a bicentric intra-individual crossover comparison of gadobenate dimeglumine with gadopentetate dimeglumine for lesion enhancement. Radiology 230: 55–64PubMed

35.

Knopp MV, Schoenberg SO, Rehm C, et al (2002) Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 37: 706–715CrossRefPubMed

36.

Völk M, Strotzer M, Lenhart M, et al (2001) Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 220: 484–488PubMed

37.

Schneider G, Maas R, Schultze Kool L, et al (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38: 85–94CrossRefPubMed

38.

Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol (Berl) 73: 145–152

39.

Finelli DA, Hurst GC, Gullapali RP, Bellon EM (1994) Improved contrast of enhancing brain lesions on post-gadolinium, T1-weighted spin-echo images with use of magnetization transfer. Radiology 190: 553–559PubMed

Titel: A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours
verfasst von: C. Colosimo
M. V. Knopp
X. Barreau
E. Gérardin
M. A. Kirchin
F. Guézénoc
K. P. Lodemann
Publikationsdatum: 01.08.2004
Verlag: Springer-Verlag
Erschienen in: Neuroradiology / Ausgabe 8/2004
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-003-1128-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2004

Bilateral orbital tumour as the presentation of mammographically occult breast cancer

T. Juroiwa, A. Baethmann, Z. Czernicki Z et al. (eds): Brain Oedema XII: Proceedings of the 12th International Symposium

Acute stenting and thromboaspiration in basilar artery occlusions due to embolism from the dominating vertebral artery

T. Moritani, S. Ekholm, P.-L. Westesson: Diffusion-Weighted MR Imaging of the Brain

Normal age-related signal change in the laryngeal cartilages